Choices between dual (ASA+clopidogrel), dual (ASA+IIb/IIIa) and triple (ASA+clopidogrel+IIb/IIIa) antiplatelet therapy are driven by risk and upon consideration of a bivalirudin only EIS: l Ischemic risk Conventional consideration in EDConventional consideration in ED Prefer triple therapy unless...Prefer triple therapy unless...
{}